N@N

Andrew Fein Reiterated (VRTX) at Strong Buy and Held Target at $380 on, Aug 2nd, 2023

Andrew Fein of HC Wainwright & Co., Reiterated "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy and Held Target at $380 on, Aug 2nd, 2023.

Andrew has made no other calls on VRTX in the last 4 months.

There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Skorney of "Baird" Maintained at Hold with Increased Target to $325 on, Tuesday, May 2nd, 2023
• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $340 on, Tuesday, May 2nd, 2023

These are the ratings of the 9 analyists that currently disagree with Andrew

---

• Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $245 on, Tuesday, August 1st, 2023
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $424 on, Monday, July 24th, 2023
• Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $400 on, Friday, July 21st, 2023
• Myles Minter of "William Blair" Initiated at Buy on, Tuesday, May 30th, 2023
• Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $385 on, Thursday, May 4th, 2023
• Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $400 on, Wednesday, May 3rd, 2023
• Jessica Fye of "JP Morgan" Maintained at Buy and Held Target at $345 on, Tuesday, May 2nd, 2023
• Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $385 on, Tuesday, May 2nd, 2023
• Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $456 on, Tuesday, May 2nd, 2023

Contributing Sources

---